Why Exact Sciences Shares Rallied 16.7% in October
After reporting third-quarter financial results that were better than expected, Exact Sciences (NASDAQ: EXAS) shares gained 16.7% in October, according to S&P Global Market Intelligence.
Exact Sciences' quarterly results show that more doctors and patients are choosing its Cologuard test for colon cancer screening.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Exact Sciences Stock
€50.05
-5.270%
Exact Sciences is currently one of the favorites of our community with 13 Buy predictions and no Sell predictions.
As a result the target price of 82 € shows a very positive potential of 63.84% compared to the current price of 50.05 € for Exact Sciences.
